Catabasis Pharmaceuticals, Inc. (CATB)
| Market Cap | 67.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -34.93M |
| Shares Out | 19.42M |
| EPS (ttm) | -2.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $2.88 |
| Previous Close | $2.85 |
| Change ($) | 0.03 |
| Change (%) | 1.05% |
| Day's Open | 2.80 |
| Day's Range | 2.73 - 2.95 |
| Day's Volume | 632,656 |
| 52-Week Range | 1.25 - 8.59 |
Catabasis Pharma (CATB) stock is soaring higher on Friday after announcing its acquisition of Quellis Biosciences and a PIPE. The post CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing To...
Investors need to pay close attention to Catabasis (CATB) stock based on the movements in the options market lately.
Catabasis Pharmaceuticals (CATB) stock is taking off on Wednesday despite a lack of news from the biopharmaceutical company. The post Catabasis Pharmaceuticals: 9 Things for Potential CATB Sto...
There are some investors who buy stocks that are trading below their liquidation value because they believe they can make remarkable gains out of their investments after the market has reasses...
Catabasis Pharmaceuticals (CATB) news for Tuesday includes incredibly poor results from a clinical trial hammering CATB stock hard. The post Catabasis Pharmaceuticals News: Why CATB Stock Is P...
Catabasis is approaching its highly anticipated Q4 readout for their Phase III PolarisDMD study. If the data is acceptable, Catabasis expects to file an NDA in 2021.
Investors need to pay close attention to Catabasis (CATB) stock based on the movements in the options market lately.
Catabasis Pharmaceuticals (CATB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Catabasis Pharmaceuticals Inc. (CATB) CEO Jill Milne on Q4 2019 Results - Earnings Call Transcript
Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.
Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q3 2019 Results - Earnings Call Transcript
Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) has announced that it completed the enrollment for its late-stage Duchenne muscular dystrophy (DMD) study.
Catabasis Pharmaceuticals (CATB) CEO, Jill Milne on Q2 2019 Results - Earnings Call Transcript
Catabasis enrollment is moving fast, having completed enrollment in certain countries, and is on track to report results from the phase 3 PolarisDMD study by second half of 2020.
Catabasis Pharmaceuticals, Inc. (CATB) CEO Jill Milne on Q1 2019 Results - Earnings Call Transcript
Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q4 2018 Results - Earnings Call Transcript
Catabasis (CATB) beats earnings estimates in the fourth quarter of 2018. The company has no revenues. Shares up.
About CATB
Catabasis Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research coll... [Read more...]
| Industry Biotechnology | IPO Date Jun 25, 2015 |
| CEO Jill C. Milne | Employees 27 |
| Stock Exchange NASDAQ | Ticker Symbol CATB |